Home REIT plc (HOME) ORD GBP0.01
Sell:38.01p
Buy:38.01p
0
Change:
No change

Market closed |
Prices as at close on 12 March 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- Create an alert
- This stock can be held in a
Sell:38.01p
Buy:38.01p
Change:
No change


Market closed |
Prices as at close on 12 March 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:38.01p
Buy:38.01p
Change:
No change

Market closed |
Prices as at close on 12 March 2025
Prices delayed by at least 15 minutes
|
Switch to live prices
|

The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Objective
The Company’s investment objective is to realise all existing investments in the Company’s portfolio in an orderly manner, with a view to ultimately returning available cash to Shareholders, following the repayment of the Company’s borrowings
Security | Weight |
---|---|
Novo Nordisk A/S Class B | 6.76% |
Astra Zeneca | 6.26% |
Boston Scientific Corp | 5.63% |
Humana Inc | 5.23% |
Intuitive Surgical Inc | 4.71% |
Merck Tbk | 3.68% |
Eli Lilly and Co | 3.60% |
Bio Marin Pharmaceutical | 3.54% |
Daiichi Sankyo Co., Ltd. | 3.53% |
Sanofi | 3.52% |
Sector | Weight |
---|---|
Healthcare | 70.63% |
Country | Weight |
---|---|
United States | 52.32% |
Denmark | 6.76% |
Indonesia | 3.68% |
Japan | 3.53% |
France | 3.52% |
Canada | 0.51% |
Cayman Islands | 0.30% |
Hong Kong | 0.18% |
China | 0.13% |
Fee Structure
The Investment Adviser is entitled to an annual fee based on NAV payable monthly in arrear calculated at the rate of i 0.85% for first GBP500 m ii 0.75 % for NAV from GBP500 m to GBP750 m and iii 0.65% fro NAV above GBP750 m. No performance fee is payable to the Investment Adviser.
Dividend Policy
On 16 February 2023, the Board announced that except for any distributions that would be required to maintain REIT status, that it has ceased paying any further dividends until further notice.
ASSET SPLIT
Trust Manager
Not currently available for this investment trust.
Manager Bio
Not currently available for this investment trust.
Board Of Directors
Michael ODonnellChairman, Peter Williams, Roderick Day
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.